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To obtain high-specific and selective forchlorfenuron binders, a collection of functionalized derivatives 
with different spacer arm locations and lengths was prepared. By immunization with target-mimicking 
haptens, a large battery of monoclonal and polyclonal antibodies against this synthetic cell regulator was 
produced and exhaustively characterized in two immunoassay formats using homologous and 10 
heterologous conjugates. Antibodies with IC50 values lower than 0.3 nM were successfully raised from 
the prepared immunogens, thus evidencing the efficacy of the explored strategies. In order to identify 
significant epitopes in the antibody–antigen interaction, a series of new chemical forchlorfenuron 
analogues, with slight modifications at both rings of the target molecule, were synthesized and evaluated 
in competitive assays. As a novel approach in hapten recognition studies, data processing was performed 15 
by computational classification methods based on hierarchical clustering. This strategy was shown to be 
highly valuable for a straightforward profiling of antibodies according to analogue recognition patterns. A 
relationship could be established between the antigen binding properties of antibodies and the structure of 
the immunogen. Whereas antibodies with equivalent affinities had been obtained from all of the 
derivatives, their specificity was found to be largely influenced by the differential exposition of the 20 
molecule to the immune system. 
Introduction 
Small organic molecules need to be covalently coupled to 
immunogenic carriers in order to obtain antibodies. Therefore, 
derivatives incorporating a functional chemical group and a 25 
spacer arm ought to be synthesized for most substances. A 
successful production of antibodies mostly relies on the structure 
of the prepared immunogen,1 and hence the immunizing hapten 
should resemble the target compound almost perfectly. It is well 
established that a certain immunizing derivative should preserve 30 
as much as possible the physicochemical characteristics of the 
target molecule (steric, electronic, and geometric properties), and 
therefore the position, composition, and length of the spacer arm 
are critical aspects in hapten design.2 Particularly, the 
derivatization site within the immunizing hapten, and thus the 35 
differential presentation of the immunogen to the immune 
system, is known to have a strong effect on antibody properties, 
especially on their specificity.3 During the last years, computer-
assisted molecular modelling techniques have been introduced 
and structure–activity relationship studies have been carried out 40 
to provide useful information with regard to immunogen design.4 
However, prediction of the structure of the perfect immunizing 
hapten still remains a challenge. Consequently, for the generation 
of high-affinity and selective antibodies, it is strongly 
recommended to prepare an assortment of compounds mimicking 45 
the analyte of interest and containing a functional linker at 
different positions, thus facilitating the presentation of the antigen 
to the immune system from a variety of perspectives. In addition, 
heterologous haptens in assay conjugates may contribute to 
increase the sensitivity of analytical immunoassays. 50 
 Forchlorfenuron is a synthetic chloropyridyl phenylurea, also 
named FCF or CPPU, which has been shown to exert varied 
biological activities. Structure–activity relationship studies on 
substituted ureas have revealed that compounds with an intact 
NH−CO−NH bridge, a phenyl ring at the N-position, and a 55 
substituted heterocyclic ring at the N’-position significantly 
enhance cell-promoting function in plants.5 In fact, CPPU 
displays an outstanding phytohormonal activity,6 exceeding that 
of the most active natural and synthetic adenine-substituted 
cytokinins, which has markedly determined its notable success as 60 
agrochemical. Additionally, CPPU alters, in a specific and 
reversible manner, the organization of septins, a family of highly 
conserved GTPase proteins involved in diverse physiological 
events including cytoskeleton organization, cell division, and 
morphogenesis in fungi and animals.7 These findings have 65 
pointed out CPPU as a very valuable candidate to help scientists 
elucidate the intricate mode of action and function of septins, as 
well as to increase their knowledge about disorders associated to 
defects in the regulation of those proteins, like cancer, Parkinson, 
or Alzheimer diseases. 70 
 We have previously described the syntheses of functionalized 
derivatives with different linker lengths or tethering sites and the 
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generation of monoclonal and polyclonal antibodies (mAbs and 
pAbs, respectively) against CPPU.8 In the present study, new 
haptens have been synthesized to screen novel derivatization 
positions in the immunizing hapten that may influence the 
properties of the produced antibodies. In the end, a large library 5 
of haptens, conjugates, mAbs, and pAbs for CPPU has been 
constructed in our lab and it is presented herein. In order to 
characterize the affinity of the available antibodies and to 
rationally select the best immunoreagents, competitive enzyme-
linked immunosorbent assays (cELISA) in the antibody-coated 10 
direct (d-cELISA) format and in the conjugate-coated indirect 
(i-cELISA) format have been employed. An extensive study was 
conducted using several heterologous competitors, including 
conjugates with site, length, and structure heterologies. Next, 
molecular epitope mapping was carried out by scanning the 15 
antibody recognition towards a collection of CPPU-analogous 
compounds that were specifically designed and synthesized with 
the aim to establish a correlation between antibody specificity 
and the structure of the employed immunogen. Moreover, an 
innovative approach to the study of the binding profiles of the 20 
antibodies was applied using an agglomerative hierarchical 
clustering methodology, which was revealed as a very suitable 
tool for the analysis of the diversity of a miscellaneous collection 
of antibodies. 
Results and discussion 25 
Hapten synthesis and conjugate preparation 
Immunogenic conjugates should allow a maximization of the 
exposition of the main antigenic determinants that are present in 
the hapten, as they presumably will rule the affinity of the 
generated antibodies based on their contribution to the molecular 30 
forces driving the antibody–antigen interaction. CPPU is a rather 
symmetric molecule which is comprised of two aromatic systems  
(phenyl and chloropyridyl rings) linked by a polar urea bridge 
(Table 1). Concerning the chemical nature of the molecule, the 
phenyl ring may contribute to hydrophobic interactions with the 35 
active site of antibodies, whereas the more polarized 2-
chloropyridyl group may get involved in electrostatic 
interactions. Additionally, the azomethynic nitrogen atom in the 
pyridyl ring and the ureido group make possible the formation of 
hydrogen bonds. Having all those considerations in mind, 40 
functionalized derivatives of CPPU with different derivatization 
sites and linker lengths were designed (Table 1). The ureido 
bridge was maintained intact in all of the derivatives, given the 
relevant participation generally attributed to this moiety in the 
molecular recognition towards phenylurea compounds.9 45 
Immunizing haptens were prepared with the spacer arm located at 
the phenyl ring, more precisely, at the para and the meta 
positions (p-type and m-type haptens, respectively), and at the 
C-2 position of the pyridyl ring through substitution of the 
chlorine atom by a thioalkyl chain (s-type haptens). The 50 
nucleophilic substitution of a chlorine atom by a 
carboxyalkylthiol group in immunizing haptens has been 
successfully employed before by other authors for the production 
of antibodies against molecules containing this halogen.3a,10 
Table 1 Chemical structure of CPPU and synthetic haptens. 
 HN
H
N
XO
R3
R1
R2  
Hapten R1 R2 R3 X 
p2a CH2CO2H H Cl N 
p6 (CH2)5CO2H H Cl N 
CldPhUp6 (CH2)5CO2H H Cl C 
PhPyUp6 (CH2)5CO2H H H N 
m2 H CH2CO2H Cl N 
m6 H (CH2)5CO2H Cl N 
s3 H H S(CH2)2CO2H N 
s5 H H S(CH2)4CO2H N 
4Fs5 F H S(CH2)4CO2H N 
4Ms5 Me H S(CH2)4CO2H N 
a Haptens used for immunogen preparation are highlighted in bold-type 
letter. 
Scheme 1 Preparation of immunizing haptens m2 and s3 
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 For the preparation of new immunizing and assay competitor 
haptens (m2, s3, 4Fs5, and 4Ms5), we followed the general 
synthetic approach commonly used for this type of compounds, 
which is based on the formation of the ureido moiety via reaction 
of a conveniently functionalized aryl- or pyridyl-amine with the 5 
appropriate isocyanate. Thus, hapten m2 (4, Scheme 1A) was 
efficiently obtained by reaction of commercially available 2-(3-
aminophenyl)acetic acid (1) with 2-chloro-4-isocyanatopyridine 
(3), which was prepared in situ, due to its high instability, in a 
one-pot reaction by Curtius rearrangement of 10 
2-chloroisonicotinoyl azide (2).8 On the other hand, the synthesis 
of hapten s3 (11, Scheme 1B) required the previous preparation 
of the aminopyridine 8, which was initiated by the reaction of 2-
chloro-4-nitropyridine N-oxide (5)12 with commercially available 
methyl 3-mercaptopropanoate (6) in the presence of Et3N as basic 15 
catalyst at reflux of benzene.11 The nucleophilic aromatic 
substitution reaction of the chlorine atom by the 
methoxyoxopropylthiol group to give compound 7 took place 
with moderate yield (54%) due, at least in part, to the competitive 
substitution reaction of the C-4 nitro group. Simultaneous 20 
reduction of the nitro and N-oxide moieties of this product with 
metallic iron afforded the required aminopyridine 8. Finally, the 
synthesis of hapten s3 was readily completed in high yield by 
reaction of 8 with phenyl isocyanate followed by basic hydrolysis 
of the ester moiety of the initially formed methyl ester 10. The 25 
synthesis of assay competitor haptens (4Fs5 and 4Ms5) was 
effected in a similar way by reaction of methyl 5-((4-
aminopyridin-2-yl)thio)pentanoate8b with 4-fluoroisocyanatoben-
zene and 1-isocyanato-4-methylbenzene, respectively, as 
described in the ESI† (Scheme S1). 30 
 Haptens were activated and coupled to bovine serum albumin 
(BSA) by the active ester method, and to ovalbumin (OVA) and 
horseradish peroxidase (HRP) by the mixted anhydride method to 
afford the immunogens and assay conjugates, respectively (see 
the ESI†). Coupling of hapten s3 to OVA and HRP by the mixed 35 
anhydride method resulted in a poorly recognized conjugate. 
Table 2  Influence of heterologous conjugates on antibody IC50 values (nM)a. 
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p2#52 0.48 0.43 0.35  0.31 0.31 0.34 0.17 0.24 0.19  p2#52 0.83 4.48 0.72  0.98 4.35  1.06 1.07 1.22 
p2#61 0.21 0.14 1.31  0.18 0.31 0.10 0.07 0.07 0.66  p2#61  0.44    0.23     
p2#65 0.42 0.22 2.87  0.21 0.52 0.22 0.12 0.18 0.17  p2#65 0.24 1.00 0.27  0.24 0.65  0.31 0.26 0.31 
p2#66 0.33 0.47   0.37 0.37 0.51 0.20 0.28 0.33  p2#66 0.29 0.57   0.18 0.44  0.21 0.23 0.22 
p6#24 0.33 0.20 0.38  0.21 0.24 0.23 0.17 0.18 0.15  p6#24  0.61 0.41   0.79  0.21 0.19  
p6#33 2.42 0.38   0.37 0.42 0.47 0.39 1.10 0.46  p6#33 0.79 1.53   0.68 4.06  0.50 0.43 0.55 
p6#41 0.31 0.45 0.61  0.14 0.23 0.15 0.23 0.20   p6#41  0.33         
p6#42 0.12 0.13 0.22  0.16 0.13 0.07 0.09 0.08 0.25  p6#42 0.42 0.60 0.53  0.37 0.67  0.28 0.40 0.25 
Rp6#1 1.36 0.49 0.42 1.14 0.80 0.55 0.27 0.30 0.31 0.67  Rp6#1 0.87 0.89 1.12  0.58 0.71  0.42 0.35 0.77 
Rp6#2 4.82 0.76 0.37 0.31 1.54 2.25 0.42 0.89 1.53 1.07  Rp6#2 1.02 2.11 1.00  0.79 1.63  0.67 0.68 0.86 
                       
m2#12 1.07 0.62   1.40 1.39 0.51  1.20   m2#12           
m2#13 1.13 1.14   1.36 1.08 0.58 1.38 0.84   m2#13      3.24     
m2#14 1.76 1.09   1.50 2.10 0.77 0.61 0.84 1.09  m2#14  0.82    0.58  0.86  0.56 
m2#15 0.25 0.16   0.22 0.47 0.41 0.19 0.32 0.27  m2#15  0.32    0.32  0.14 0.14 0.15 
m6#13 0.36 0.71 0.59  0.20 0.24 0.55 0.22 0.31 0.24  m6#13  0.44    0.47  0.32 0.34 0.27 
m6#31 1.67 0.89   1.12 1.06 0.83 1.42 0.88 0.88  m6#31  1.41    0.70     
m6#42 0.63 0.95 0.31  0.50 0.81 1.39 1.02 0.95 0.82  m6#42 0.74 1.81 0.70   2.00  1.01 1.00 0.96 
m6#43 0.47 0.64 0.79  0.90 0.68 3.10  1.09 0.88  m6#43  1.45 0.53   1.52     
Rm6#1 1.01 0.28 0.83  0.20 0.45 0.41 0.55 0.54 0.45  Rm6#1  0.53 1.07   0.65  0.61 0.46 0.60 
Rm6#2 0.93 1.01 1.18  0.60 1.16 0.86 0.92 1.60 0.92  Rm6#2  0.63 1.35   1.28  0.83 0.63 0.62 
                       
s3#22 1.67 1.94 1.95  1.12 1.64 2.04 1.94 2.03 1.26  s3#22  1.04 3.51   1.22  1.11 1.26 1.62 
s3#51 0.08 0.25 0.27  0.10 0.11 0.23 0.14 0.48 0.64  s3#51  0.17 0.25   0.36 0.22 0.56 0.46 0.27 
s3#52 0.21    0.14 0.26 0.18 0.22 0.24 0.33  s3#52      0.98  0.25 0.26 0.20 
s3#54 0.20  0.65    0.10 0.14 0.12 0.10  s3#54        0.29 0.21  
s5#12 0.55 0.93 0.47  0.42 0.88 0.98 0.46 0.75 0.43  s5#12  0.37 1.36   0.53  0.92 0.65 0.32 
s5#32 0.99  0.23  0.83 0.82 0.12 0.12 0.11 0.10  s5#32   0.36    0.51 0.59 0.40 0.30 
s5#33 0.08 0.08 0.28  0.08 0.09 0.11 0.10 0.09 0.18  s5#33  0.25 0.20   0.21 0.21 0.29 0.27 0.25 
s5#34 0.21 0.15 0.47  0.35 0.24 0.29 0.26 0.26 0.10  s5#34  0.21 0.40   0.23 0.45 0.37 0.42 0.26 
Rs5#1 0.85 0.65 0.44  0.76 0.33 0.44 0.35 0.65 0.64  Rs5#1  0.47 0.97   0.88 1.10 0.30 0.30 0.26 
Rs5#2 0.25 0.33 0.60  0.72 0.47 0.54 0.36 0.85 0.67  Rs5#2  0.36 0.67   0.44 0.82 1.38 0.99 0.86 
a No data are given if the Amax did not reach the value of 1.0. Cell colors represent the combinations which improved at least two-fold the sensitivity of the 
homologous assay. For those antibodies that did not recognize the homologous tracer in the d-cELISA format, the IC50 value of the heterologous tracer with a longer 
linker was employed as reference. b Antibodies are listed according to the immunogen (p2 or p6, m2 or m6, and s3 or s5). Rabbit polyclonal antibodies are indicated 
by a capital R letter. 
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Attempts to isolate the anhydride were unsuccessful, and 
therefore s3 was conjugated to OVA and HRP by the active ester 
method. The obtained hapten-to-protein molar ratios of all 
available conjugates are listed in Table S1. Those values were 
consistent with the number of free ε-amines available in the 5 
carriers. 
Animal immunization and monoclonal antibody production 
In previous studies, mAbs against CPPU had been prepared using 
haptens with the spacer arm at the para position of the 
phenylurea ring and with different lengths (p2 and p6) as 10 
immunizing haptens.8a To complete our collection of mAbs, mice 
were immunized with conjugates of m-type and s-type haptens 
(BSA–m2, BSA–m6, BSA–s3, and BSA–s5). A summary of the 
mAb-generation process is reported in Table S2 of the ESI†. To a 
set of 17 mAbs previously generated using haptens p2 and p6, 21 15 
novel antibodies were added: 4 cell lines from mice immunized 
with BSA–m2, 4 from BSA–m6, 6 from BSA–s3, and 7 from 
BSA–s5. All of the produced mAbs were of the IgG1 isotype 
(only mAb m6#43 was of the IgG2b isotype) with a κ-type light 
chain. Additionally, 6 pAbs had been generated from rabbits 20 
immunized with the three site-heterologous haptens containing 
the longer linker (p6, m6, and s5).8 
Structure-activity relationship 
Evaluation of antibody affinity 
A preliminary characterization of a set of 38 mAbs was 25 
performed in two cELISA formats using coating conjugates or 
enzyme tracers carrying the homologous hapten, that is, the same 
synthetic derivative used for immunization. Antibody affinity was 
estimated from the concentration of analyte at the inflection point 
of the fitted inhibition curve, typically corresponding to a 50% 30 
reduction (IC50) of the maximum absorbance (Amax) if the 
background signal approaches to zero. As a foremost result, an 
IC50 value below 1.0 nM was displayed by 70% of the mAbs in 
the i-cELISA format, and by 38% of the mAbs in the d-cELISA 
format. High-affinity antibodies could be produced from all 35 
immunogens, independently of the derivatization site and linker 
length of the hapten. Based on this study, 4 mAbs from each 
immunizing conjugate were selected. With the aim of assessing 
the effect of hapten heterology on the apparent affinity of the 
generated antibodies, heterologous conjugates were also 40 
employed in both cELISA formats. For each combination of 
immunoreagents different concentrations were tested, so a 
collection of inhibition curves with different Amax values was 
obtained. Table 2 summarizes this study for the selected 24 mAbs 
and the 6 available rabbit pAbs. The diversity of the prepared 45 
haptens allowed us to find some heterologous combinations 
which could lower the IC50 values. Cell color in Table 2 indicates 
the heterologous combinations that provided IC50 values lower 
than the homologous one. Around one third of the mAbs clearly 
improved their binding to CPPU using heterologous conjugates. 50 
 Although it was difficult to draw solid conclusions about the 
type of heterology that exerted a higher improvement on the IC50 
values of antibodies, some general trends were observed. First, 
linker-length heterology was not shown as a very effective 
strategy. Second, structural heterology resulted in rare 55 
improvements on assay sensitivity; conjugates based on haptens 
4Fs5 and 4Ms5, with modifications at the phenyl ring, were better 
recognized and performed finer than those employing haptens 
with changes at the chloropyridyl ring, i.e. haptens CldPhUp6 and 
PhPyUp6. Third, site-heterology was revealed as the most 60 
successful approach, as the vast majority of the combinations that 
afforded improved CPPU recognition were based on haptens with 
the spacer arm at a position different to that of the immunizing 
hapten. Fourth, enzyme tracers with short spacer arms were 
mostly not recognized; this experimental observation has been 65 
frequently documented for other antigens.13 Fifth, it was found 
that the response of every particular antibody was not parallel in 
both assay formats. As it generally happens,14 the d-cELISA 
format showed a more restrictive recognition pattern towards 
assay conjugates than the i-cELISA format. Finally, the 70 
behaviour of the pAbs was equivalent to that shown by the mAbs, 
although pAbs generally displayed a broader recognition profile 
of heterologous conjugates. This result may be attributed to the 
fact that the pAbs  
represent the raw response of the animal immune system, and 75 
therefore they comprise immunoglobulins with heterogeneous 
properties. 
 Figure 1 shows a representative inhibition curve for one mAb 
from each functionalization site in both cELISA formats, using as  
selection criteria the apparent affinity of the antibody and the 80 
slope of the inhibition curve. Those curves had Amax values 
Figure 1 CPPU inhibition curves of the selected antibodies in two cELISA formats. Values are the average 
of three independent experiments 
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around 1.0 and showed IC50 values below 0.3 nM and slopes 
around −1.2. A detailed list of the parameters of the depicted 
curves is provided in Table S3 of the ESI†. 
Binding studies by hierarchical clustering analysis 
The evaluation of antibody–antigen interactions has opened the 5 
door to promising biomedical applications in the diagnosis, 
prognosis, and therapeutic fields, or even in vaccine development 
research.15 Assessment of antibody specificity is traditionally 
conducted by cross-reactivity studies, where a set of molecules 
structurally related to the target analyte are evaluated as 10 
competitors. By studying the analogue recognition (AR) pattern 
of antibodies, the major antigenic determinants within the target 
molecule can be disclosed. Nevertheless, the heterogeneity 
sometimes displayed by antibodies can make it difficult to 
establish a relationship between the structure of the immunizing 15 
hapten and the binding properties of the antibodies, just by direct 
and non-assisted evaluation of the competitive experiments. To 
overcome this limitation, we have performed a wide analysis of 
the AR pattern for a large panel of antibodies and we have 
applied computer-assisted clustering methodologies in order to 20 
classify the immunoglobulin repertoire. These informatics tools, 
commonly employed in genomic and transcriptomic analysis, 
have been proven as very helpful instruments to correlate and to 
assist the comprehension of large sets of data from proteomic 
studies16 and they have also been applied to profiling antibody 25 
binding properties to proteins or peptides.17 Recently, Pattathil et 
al.18 published the application of this agglomerative method in 
order to group mAbs, based on plant cell wall polysaccharide 
recognition patterns. In the present study, hierarchical clustering 
analysis has been applied for the first time to the evaluation of the 30 
specificity of antibodies generated against a small organic 
molecule. To determine the binding properties of 38 mAbs and 6 
rabbit pAbs that were produced against CPPU, a study was 
carried out using a group of synthetic compounds (see the 
Experimental section) which are chemically related to CPPU (see 35 
the list and their abbreviations in Table 3). Those analogues could 
be classified into three categories depending on the chemical 
modification under consideration: first, chemicals with changes at 
the phenyl ring (4FPhClPyU, 4MePhClPyU, F5PhClPyU, and 
CldPyU); second, analogues with changes at the chloropyridyl 40 
ring (PhBrPyU, PhdClPyU, PhPyU, dPhU, NdPhU, and CldPhU);  
and third, those with modifications at the urea bridge (thio-CPPU 
and BzClPyA). Additionally, the recognition of herbicide 
thidiazuron (TDZ), which presents a thiadiazole ring instead of 
the characteristic chloropyridyl ring of CPPU, was also assessed. 45 
From the data matrix of AR values of those compounds, a 
specificity heat map was generated as illustrated in Figure 2A. 
Also a dendrogram was created (see the left of the heat map) to 
easily classify the antibodies according to their specificity 
profiles by implementing a hierarchical clustering algorithm19 50 
using the MeV software (see the Experimental section). In that 
classification tree, the antibodies represented in closer positions 
are mathematically the most similar, and therefore the distance 
between clusters (groups of antibodies) can be correlated to the 
similarity of the binding profiles. As it can be observed, two well 55 
differentiated groups of antibodies had been generated by 
immunization with six CPPU derivatives. The first cluster, called 
A (light green bar), included only antibodies obtained from 
immunizing haptens that had been functionalized at the phenyl 
ring (p2, p6, m2, and m6), whereas the second cluster, called B 60 
(pink bar), was composed mainly of antibodies obtained from 
haptens derivatized at the chloropyridyl ring (s3 and s5). 
Antibodies belonging to cluster A seemed to be more permissive 
to changes in the structure of the phenyl ring of the competing 
analogues (4FPhClPyU, 4MePhClPyU, F5PHCLPYU, and 65 
CldPyU) than antibodies of cluster B. A clear example of the 
differential response between both groups was observed for 
compound CldPyU. Most antibodies of cluster A were able to 
recognize this chemical to a similar extent or even better than 
CPPU, whereas for antibodies of cluster B, the distal substitution 70 
of the phenyl ring by a pyridyl ring (as in CldPyU) caused a 
noticeable disturbance in the recognition. On the contrary, lower 
AR values towards compounds with modifications at the 
chloropyridyl ring (PhBrPyU, PhdClPyU, PhPyU, dPhU, NdPhU, 
and CldPhU) were generally found for antibodies in cluster A 75 
than for antibodies in cluster B. This trend was especially evident 
for compounds NdPhU and CldPhU, which were characterized by 
the substitution of the 2-chloropyridyl ring by a nitrophenyl and 
chlorophenyl ring, respectively (see Table 3). This observation 
highlighted the important role of the nitrogen atom of the 80 
pyridine ring in the interaction of the antibodies with CPPU. 
Altogether, these findings were in agreement with the 
Landsteiner’s principle,20 as antibodies showed a higher 
interaction with those moieties distally located from the 
Table 3 Chemical structures of the CPPU analogues used as 
competitors in the AR studies. 
H
N
H
N
NO
R6
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R4
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R2 R7
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Compounda R1 R2 R3 R4 R5 R6 R7 
4FPhClPyU H H F H H Cl H 
F5PhClPyU F F F F F Cl H 
PhdClPyU H H H H H Cl Cl 
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PhBrPyU H H H H H Br H 
PhPyU H H H H H H H 
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attachment site of the spacer arm. In contrast, modifications at 
positions closer to the derivatization site were better tolerated. 
The classification of the antibodies based on hierarchical 
clustering analysis clearly evidenced that the position of the 
functionalized arm within the immunizing hapten, and hence the 5 
variation in the displayed orientation of the CPPU framework, 
had a significant influence on antibody specificity.  
 Both clusters A and B could be further subdivided into two 
branches, called A1 and A2, and B1 and B2, respectively. To 
better visualize differences among clusters, the AR profile of a 10 
representative mAb from each group has been depicted in Figure 
2B. The main difference among antibodies of branches A1 (dark 
red line) and A2 (orange line) was the recognition of compounds 
F5PhClPyU and PhdClPyU. Whereas antibodies of branch A1 
showed a certain tolerance towards the presence of five 15 
fluorineatoms at the phenyl ring (F5PhClPyU), antibodies of 
branch A2 were clearly more susceptible to this electronic 
modification, following a more similar behavior to some 
antibodies in cluster B. In contrast, the presence of two chlorine 
atoms at the pyridyl ring (PhdClPyU) was quite well tolerated by 20 
most antibodies of branch A2. Regarding cluster B, antibodies 
comprising branch B1 (blue line) presented a narrower binding 
profile than those included in branch B2 (dark green line), as 
evidenced by the lower AR values of the former antibodies, thus 
being more sensitive to modifications in the CPPU structure. 25 
Both Rp6-type and both Rm6-type rabbit pAbs shared their 
binding profiles with antibodies of cluster A (branch A1), 
whereas both Rs5-type rabbit pAbs were included into cluster B 
(branch B1), as it would be expected attending to the hapten from 
which they were derived. 30 
 Some other significant findings with respect to relevant 
epitopes in the target molecule were ascertained from the analysis 
of the binding heat map (Figure 2A). First, PhBrPyU was 
perfectly recognized by all of the antibodies, independently of 
their origin. On the contrary, a general loss of binding was 35 
observed for compound PhPyU, that is, the analogue lacking the 
chlorine atom (see Table 3). These results suggested that the 
presence of an electron-withdrawing element at the C-2 position 
of the pyridyl ring was highly important, being chlorine and 
bromine atoms perfectly exchangeable, as also observed by other 40 
authors with different targets.21 The significance of the presence 
of a polarized area in the antigen was also supported by the high 
recognition displayed by some antibodies towards analogue 
PhdClPyU. Similar results were found by Schneider et al.22 for 
antibodies produced against the phenylurea herbicide monuron. 45 
Accordingly, the modification of the urea bridge in phenylurea 
compounds has often been found to cause a disturbance in the 
antibody recognition.23 The strong contribution of the urea bridge 
to the antibody–antigen interaction was revealed by a general 
decrease in the recognition of the thiourea analogue (thio-CPPU), 50 
Figure 2 Analysis of the binding properties of the antibodies to a set of CPPU analogous compounds. A) Heat map visualization of the 
logarithm of AR data matrix and the generated dendrogram using the hierarchical Kendall’s Tau similarity metric and complete linkage 
as the aggregation method. Black represents 100% binding. Intense green means that AR was much over 100%, whereas intense red 
means that binding was much lower than 100%. B) AR profiles of representative antibodies of the main clusters of the dendrogram. C) 
Correlation between the original immunizing hapten and antibody distribution within the clusters.  
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and especially by an almost undetectable binding to the amide 
analogue (BzClPyA). The lower recognition of the structurally 
similar thio-CPPU can be probably attributed to the different 
hydrogen bond pattern showed by the ureido and thioureido 
moieties due to the higher acidity of the thioureidic hydrogens 5 
and, particularly,  the much weaker hydrogen-bond acceptor 
capability of the thiocarbonyl group.24 Concerning TDZ 
recognition, a highly diverse binding was observed; some mAbs, 
such as p6#23, showed low AR values, whereas other antibodies 
such as s5#12 presented  recognition over 100%. The medium-to-10 
high binding pattern displayed by most of the mAbs to TDZ 
represents a clear indication of the bioisosterism25 that occurs 
between the chloropyridine and the thiadiazole moieties. Finally, 
chemicals with just one of the aromatic rings such as 4-amino-2-
chloropyridine and N-phenylurea, or with no ring at all such as 15 
N,N’-dimethylurea, were not recognized, thus indicating the 
contribution of the whole molecule to a tight interaction with the 
antibody binding site. 
 Based on the results herein presented, it could be hypothesized 
that the interaction between the generated antibodies and CPPU 20 
could be in first instance mainly driven by electrostatic forces, 
being in this sense the polarization associated to the 
2-chloropyridyl ring highly determinant. Then, the antibody–
antigen complex may be strengthened by formation of hydrogen 
bonds involving the ureido group and/or the nitrogen atom of the 25 
chloropyridyl ring. These results would fit with a cave-like 
binding pocket characteristic of hapten–antibody interactions.26 
Recently, Kopečný et al.27 resolved the crystal structure of CPPU 
in a complex with enzyme ZmCKO1, a cytokinin 
oxidase/dehydrogenase of Zea mays which becomes inactivated 30 
upon binding with this synthetic phytoregulator. In the most 
feasible conformation, the 2-chloropyridyl ring is internally 
oriented to interact with the enzyme cofactor, thus allowing the 
stabilization of the enzyme–substrate interaction probably by the 
formation of hydrogen bonding between the hydrogen atoms in 35 
the urea bridge and a neighbouring aspartic acid residue within 
the active site. 
 As observed in Figure 2C, no disparity on antibody specificity 
was found regarding the derivatization positions, para or meta, at 
the phenyl ring, as antibodies obtained from those immunogens 40 
were similarly distributed within cluster A, with few antibodies 
included in cluster B. On the other hand, s-type antibodies 
(coming from haptens derivatized at the pyridyl ring) were all 
included in cluster B and evenly distributed among both 
subgroups. With respect to the spacer arm, it was observed that 45 
the assayed linker lengths generated equivalent specificity 
responses. As a final approach, the whole collection of antibodies 
was used to create a heat map representing the antibody distance 
(Figure 3). The minimum and maximum Kendall’s tau (τ) 
correlation coefficients extracted from the comparison between 50 
the four clusters, and the corresponding pairs of antibodies are 
listed in Table S4 in the ESI†. A higher similarity was found 
among antibodies included in cluster A, especially in branch A2 
(τmin = 0.60; τmax = 0.98), than among antibodies in cluster B (τmin 
= 0.01; τmax = 0.80 for branch B1). Therefore, it could be 55 
concluded that immunogens of the p-type and m-type generated a 
more homogeneous immune response in terms of specificity than 
immunogens of the s-type. 
Conclusions 
Monoclonal antibodies with peculiar or somehow deviated 60 
behaviours from the average response are occasionally 
generated.28 In this study, the high number of available antibodies 
allowed us to establish a correlation between immunogen 
structure and antibody specificity. Good molecular mimicking 
was achieved by all immunizing derivatives as reflected by the 65 
high affinity of the generated antibodies. For sensitivity 
improvement, modification of the functionalization site of the 
assay competitor was demonstrated as the most successful 
approach. Besides, the applied strategy using chemical analogues 
was especially useful for gaining some insights into the most 70 
significant epitopes involved in the antibody−antigen interaction. 
Also, the potential of computer-assisted classification techniques 
as complementary tools for the comprehension of the diversity of 
the generated immune response towards a small chemical 
molecule has been demonstrated. The recently discovered 75 
influence of CPPU in septin organization could make the 
synthesized chemicals and the developed antibodies herein 
described very useful reagents in basic research about this 
important family of proteins. 
Experimental 80 
Analytical-grade standard forchlorfenuron [1-(2-chloro-4-
pyridyl)-3-phenylurea, CAS Registry No. 68157-60-8, MW 247.7 
g/mol] was purchased from Sigma-Aldrich-Fluka (Madrid, 
Spain). Chemical reactions were monitored by thin-layer 
Figure 3 Heat map visualization of the antibody-distance matrix 
obtained by implementation of Kendall’s tau similarity metric. The 
measures are represented in a scale ranging from 0 (highest 
similarity, blue) to 1 (lowest similarity, yellow), indicating perfect 
agreement and disagreement for every pair of antibodies, 
respectively. 
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chromatography with 0.25 mm precoated silica gel plates. The 
synthesized chemicals were purified by flash column 
chromatography on silica gel 60 (particle size = 40–63 µm). 
Melting points were obtained in a Kofler hot-stage apparatus or a 
Büchi melting point apparatus and are uncorrected. 5 
 Carrier proteins, adjuvants, fetal bovine serum (FBS), culture 
media, and other biochemical reagents were from Sigma-Aldrich 
(Madrid, Spain) or Roche Applied Science (Mannheim, 
Germany). Purification of protein–hapten conjugates and 
antibodies was carried out in Sephadex G-25 HiTrap Desalting 10 
columns and HiTrap Protein G HP columns, respectively, 
acquired from GE Healthcare (Uppsala, Sweden). P3-X63-
Ag8.653 mouse plasmacytoma cell line was obtained from the 
European Collection of Cell Cultures (Wiltshire, UK). Polyclonal 
goat anti-rabbit immunoglobulin peroxidase conjugate 15 
(GAR−HRP) was purchased from Bio-Rad (Madrid, Spain) and 
polyclonal rabbit anti-mouse immunoglobulin peroxidase 
conjugate (RAM−HRP) was from Dako (Glostrup, Denmark). 
Hapten synthesis 
Although most of the chemicals used in this work present minor 20 
or usual safety concerns, it is recommended to take special 
caution for the handling of acyl azides and isocyanates. The 
syntheses of haptens p2, p6, m6, s5, CldPhUp6, and PhPyUp6 
were described in previous articles.8 The procedures employed 
for the synthesis of immunogens m2 and s3 (Scheme 1) were as 25 
explained below. The details of the synthesis of assay derivatives 
4Fs5 and 4Ms5 (Scheme S1), and the spectroscopic 
characterization data of the new compounds are given in the ESI†. 
Synthesis of hapten m2 
To prepare hapten m2 (4), the commercial 30 
2-(3-aminophenyl)acetic acid (1) was reacted with 2-chloro-4-
isocyianatopyridine (3). A solution of 2-chloroisonicotinoyl azide 
(2, 149 mg, 0.82 mmol)12 in toluene (1.0 mL) was added drop 
wise to a stirred solution of 1 (117 mg, 0.78 mmol) in anhydrous 
toluene (1.2 mL) at reflux under inert atmosphere. The reaction 35 
mixture was stirred for 1.5 h at reflux and then cooled to rt. The 
solid was collected by filtration and washed with toluene and 
ethyl ether, and dried under vacuum to give pure 
2-(3-(3-(2-chloropyridin-4-yl)ureido)phenyl)acetic acid, hapten 
m2 (4, 200 mg, 85%) as a white solid: mp 197–202 ºC (from 40 
toluene).  
Synthesis of hapten s3 
2-(3-Methoxy-3-oxopropylthio)-4-nitropyridin N-oxide (7) 
A solution of the commercial methyl 3-mercaptopropionate (6, 
904 µL, 8.35 mmol) and Et3N (1.16 mL, 8.35 mmol) in dry 45 
benzene (10 mL) was drop wise added to a stirred suspension of 
2-chloro-4-nitropyridine N-oxide (5, 1.18 g, 6.76 mmol)29 in 
benzene (23 mL) at reflux under argon. The reaction mixture was 
refluxed overnight and then concentrated at reduced pressure. The 
residue obtained was dissolved in CH2Cl2 and washed with water 50 
and brine. The organic layer was then dried over Na2SO4 and 
concentrated under vacuum. The residue obtained was purified by 
silica gel chromatography, using hexane/EtOAc 1:1 as eluent, 
affording the methyl ester 7 (938 mg, 54%) as a yellow solid: mp 
112–114 ºC (from benzene). 55 
Methyl 3-((4-aminopyridin-2-yl)thio)propanoate (8) 
 Iron powder (1.00 g, 17.90 mmol) and NH4Cl (448 mg, 8.37 
mmol) were added to a refluxed solution of compound 7 (819 mg, 
3.17 mmol) in a 4:1 mixture of EtOH/H2O (25 mL). The reaction 
was stirred vigorously at reflux for 30–40 min, then cooled down 60 
to rt and filtered through a short pad of celite, using MeOH to 
wash. The filtrate was concentrated under reduced pressure, 
diluted with CHCl3, washed with saturated aqueous solution of 
Na2CO3 and brine, and dried over Na2SO4. The residue was 
purified after concentration at vacuum by chromatography, using 65 
CHCl3/MeOH 9:1 as eluent, to give the amino ester 8 (592 mg, 
88%) as a yellowish oil. 
Methyl 3-(4-((3-phenylureido)pyridin-2-yl)thio)propanoate (10) 
 Phenyl isocyanate (9, 298 µL, 2.74 mmol) was added drop 
wise to a solution of methyl 3-((4-aminopyridin-2-yl)thio) 70 
propanoate (8, 466 mg, 2.20 mmol) in anhydrous benzene (8 mL) 
under argon. The reaction was stirred at reflux for 3 h and then 
concentrated under reduced pressure. The residue was purified by 
column chromatography, using CHCl3/MeOH 95:5 as eluent, to 
give urea-methyl ester 10 (620 mg, 85%) as a white solid: mp 75 
131–133 ºC (from benzene). 
3-(4-((3-Phenylureido)pyridin-2-yl)thio)propanoic acid (11, 
hapten s3) 
 A solution of the urea-methyl ester 10 obtained above (190 
mg, 0.57 mmol) in a mixture of THF (4.5 mL) and H2O (2.0 mL) 80 
was treated with LiOH·H2O (241 mg, 5.75 mmol). After 3 h 
under stirring at rt, the reaction mixture was diluted with H2O (20 
mL) and extracted with ethyl ether. Following removal of the 
remaining organic solvent under vacuum, the aqueous layer was 
cooled on ice and acidified with KHSO4 to nearly pH 3. The 85 
obtained precipitated was filtered off, washed with water and 
dried to give the crude product that was purified by column 
chromatography, using CH2Cl2/MeOH 7:3 as eluent, to afford 
hapten s3 (11, 128 mg, 70%) as a white solid: mp 178–183 ºC 
(from DMSO/H2O). 90 
CPPU analogues 
The chemical structures of all of the employed CPPU analogues 
are depicted in Table 3. TDZ (1-phenyl-3-(1,2,3-thiadiazol-5-
yl)urea), dPhU (1,3-diphenylurea), CldPhU (1-(3-chlorophenyl)-
3-phenylurea), NdPhU (1-(3-nitrophenyl)-3-phenylurea), and 95 
PhPyU (1-(4-pyridyl)-3-phenylurea) were obtained from Sigma-
Aldrich-Fluka (Madrid, Spain). The syntheses of 4FPhClPyU (1-
(2-chloro-4-pyridyl)-3-(4-fluorophenyl)urea), F5PhClPyU (1-(2-
chloro-4-pyridyl)-3-(2,3,4,5,6-pentafluorophenyl)urea), 4MePhCl 
PyU (1-(2-chloro-4-pyridyl)-3-p-tolylurea), PhdClPyU (1-(2,6-100 
dichloro-4-pyridyl)-3-phenylurea), CldPyU (1-(2-chloro-4-
pyridyl)-3-(4-pyridyl)urea), and PhBrPyU (1-(2-bromo-4-
pyridyl)-3-phenylurea) were previously described.8 The 
preparation of compounds thio-CPPU (1-(2-chloro-4-pyridyl)-3-
phenylthio urea) and BzClPyA (N-(2-chloro-4-pyridyl)-2-105 
phenylacetamide) and their spectroscopic characterization data 
are detailed in the ESI† (Scheme S2). 
Protein–hapten conjugates 
BSA was selected for the preparation of immunogens via 
activation of the carboxylate group of haptens with the active 110 
ester method, followed by formation of amide bonds with the free 
amino groups of the carrier protein. OVA and HRP were used as 
carriers for the i-cELISA and the d-cELISA formats, respectively. 
These assay conjugates were prepared by the mixed anhydride 
method. For details see the ESI†. The final hapten-to-protein 115 
Page 10 of 54Organic & Biomolecular Chemistry - For Review Only
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  9 
molar ratios of the conjugates were estimated by monitoring the 
UV–vis spectra, assuming that the molar extinction coefficients 
of both species were essentially the same before and after the 
conjugation. 
Antibody production 5 
Mice and rabbits were immunized with BSA conjugates. The 
production of pAbs from haptens p6, m6 and s5 has been 
described elsewhere.8 Also, a panel of mAbs directed against 
CPPU was previously generated from haptens p2 and p6.8a For 
the present study, our collection of anti-CPPU mAbs was 10 
increased and diversified from mice immunized with BSA 
derivatives of m2, m6, s3, and s5. The selection of hybridomas 
was conducted by differential i-cELISA30 using microplates that 
were previously coated with the homologous conjugate at 1.0 
µg/mL, and using 1 µM CPPU as competitor. Stable antibody-15 
secreting clones were finally cryopreserved in liquid nitrogen and 
cell cultures were expanded for the production of mAbs. For 
further details see the ESI†. 
Competitive immunoassays 
Solutions of all competitors were prepared in anhydrous N,N-20 
dimethylformamide and stored in amber glass vials at –20 ºC. 
Ninety six-well polystyrene ELISA plates were coated overnight 
with 100 µL per well of 50 mM sodium carbonate–bicarbonate 
buffer, pH 9.6 containing the corresponding immunoreagent. 
After incubations steps, plates were washed four times with 0.15 25 
M NaCl containing 0.05% (v/v) Tween 20. Standard curves were 
prepared by serial dilutions in 10 mM sodium phosphate-buffered 
saline (140 mM NaCl), pH 7.4 (PBS). The competitive step was 
carried out in coated microplates by mixing 50 µL per well of 
competitor solution and 50 µL per well of the corresponding 30 
immunoreagent solution in PBS containing 0.05% (v/v) Tween 
20 (PBST). In the case of i-cELISAs, the retained 
immunoglobulins were detected with an additional step using 100 
µL per well of secondary antibody dilution in PBST (1/10000 
GAR–HRP and 1/2000 RAM–HRP for pAb and mAb-based 35 
assays, respectively). After washing, the enzymatic activity was 
revealed using 100 µL per well of 2.0 mg/mL o-
phenylenediamine and 0.012% (v/v) H2O2 in 25 mM sodium 
citrate and 62 mM sodium phosphate buffer, pH 5.4. Colour 
development was stopped by addition of 100 µL per well of 2.5 40 
M H2SO4. Assay times were 1 h for each immunological reaction 
and 10 min for signal development. All incubations were carried 
out at rt. ELISA absorbance was read in dual wavelength mode 
(492 nm with 650 nm as reference wavelength) and the signal 
intensity was plotted against the analyte concentration in a 45 
logarithmic scale. The resulting sigmoidal curve was 
mathematically fitted to a four-parameter logistic equation using 
the SigmaPlot software package from SPSS Inc. (Chicago, IL).  
Binding studies and hierarchical clustering analysis 
The capability of the antibodies to recognize a battery of CPPU-50 
analogous compounds was evaluated by conducting competitive 
experiments in the i-cELISA format using homologous coating 
conjugates. Standard curves of all chemicals were prepared in 
PBS from concentrated stock solutions. AR was expressed as the 
percentage of the ratio between the IC50 value for CPPU and the 55 
IC50 value for the analogue. The binding profiles of all of the 
antibodies towards the evaluated chemicals were used to 
determine the similarity between immunoglobulins with respect 
to their specificity. With this purpose, a matrix of data was 
generated from the base-2 logarithmic transformation of the AR 60 
values normalized to the unit. The corresponding heat map and 
the dendrogram were constructed with the MultiExperiment 
Viewer (MeV) version 4.5.1 (http://www.tm4.org/mev), which is 
a part of the TM4 Microarray Software Suite.31 The hierarchical 
classification of antibodies was performed using non-parametric 65 
Kendall’s Tau similarity metric and complete linkage as the 
aggregation method. The antibody distance heat map was 
generated in the MeV programme by representing the distance 
matrix, and imposing the clustering result obtained previously.  
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1. General spectroscopic techniques 
NMR spectra were recorded in CDCl3 or DMSO-d6 at room temperature on a Bruker AC-300 
spectrometer (300.13 MHz for 1H and 75.47 MHz for 13C). The spectra were referenced to residual 
solvent protons in the 1H NMR spectra (7.26 and 2.50 ppm) and to solvent carbons in the 13C NMR 
spectra (77.00 and 39.43 ppm). Carbon substitution degrees were established by distortionless 
enhancement by polarization transfer pulse sequences. A combination of correlation spectroscopy 
and heteronuclear single quantum coherence experiments was used for the assignment of 1H and 13C 
chemical shifts. IR spectra were measured as thin films between NaCl plates and KBr pellets for 
liquid and solid compounds, respectively, in a Nicolet Avatar 320 spectrometer. Electron-impact 
(EI) and fast atom bombardment (FAB) mass spectra (MS and HRMS) were carried out in a 
Micromass VG Autospec spectrometer. Extinction coefficients were calculated in 100 mM sodium 
phosphate buffer, pH 7.4 (PB). 
 
2. Spectroscopic characterization data of haptens m2 and s3 and intermediates of their 
synthesis (Scheme 1 in the article) 
2-(3-(3-(2-Chloropyridin-4-yl)ureido)phenyl)acetic acid (4, hapten m2) 
1H NMR (DMSO-d6), δ: 12.33 (1H, br s, OH), 9.32 and 8.99 (1H each, each s, two NH), 8.17 (1H, 
d, J = 5.9 Hz, H-6 Py), 7.66 (1H, d, J = 1.8 Hz, H-3 Py), 7.39 (1H, br s, H-2 Ph), 7.33 (1H, m 
partially overlapped with dd at 7.31, H-4 Ph), 7.31 (1H, dd, J = 5.7, 1.9 Hz, H-5 Py), 7.24 (1H, t, J = 
7.7 Hz, H-5 Ph), 6.91 (1H, br d, J = 7.6 Hz, H-6 Ph), 3.53 (2H, s, H-2); 13C NMR 
(CDCl3/DMSO-d6), δ: 172.59 (C-1), 151.82 (NCON), 150.96 (C-4 Py), 149.93 (C-6 Py), 149.12 
(C-2 Py), 138.74 (C-3 Ph), 135.68 (C-1 Ph), 128.72 (C-5 Ph), 123.79 (C-6 Ph), 119.56 (C-2 Ph), 
117.05 (C-4 Ph), 111.88 (C-3 Py), 111.24 (C-5 Py), 40.80 (C-2); IR (KBr): 3400–2130, 1715, 1460–
1620, 1375, 1183, 778, 723, 641, 443 cm−1; MS (EI) m/z: 305 (M+, 7.3), 287 (2), 261 (9), 177 (33), 
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154 (86), 151 (100); HRMS: calcd for C14H12ClN3O3 305.05672, found 305.05541; UV (PB), ε (280 
nm) = 11.35 mM−1cm−1, ε (260 nm) = 28.19 mM−1cm−1. 
3-((4-(3-Phenylureido)pyridin-2-yl)thio)propanoic acid (11, hapten s3) 
2-(3-Methoxy-3-oxopropylthio)-4-nitropyridine N-oxide (7): 
1H NMR (CDCl3), δ: 8.31 (1H, d, J = 7.2 Hz, H-6 Py), 8.03 (1H, d, J = 3.0 Hz, H-3 Py), 7.89 (1H, 
dd, J = 7.2, 3.0 Hz, H-5 Py), 3.67 (3H, s, OCH3), 3.28 (2H, t, J = 7.2 Hz, H-1), 2.82 (2H, t, J = 7.2 
Hz, H-2); 13C NMR (CDCl3), δ: 170.98 (C-3), 153.88 (C-2 Py), 142.52 (C-4 Py), 139.08 (C-6 Py), 
115.62 and 114.92 (C-3 and C-5 Py), 52.30 (OCH3), 32.46 (C-2), 25.69 (C-1); IR (KBr): 3100, 
3073, 3015, 2950, 1739, 1574, 1522, 1458, 1434, 1197, 1147, 873, 744, 651 cm−1; MS (EI), m/z: 258 
(M+, 22), 242 (25), 241 (70), 227 (16), 225 (7), 211 (15), 209 (100), 199 (16), 183 (44), 182 (35), 
172 (46), 163 (23),153 (24); HRMS: calcd for C9H10N2O5S 258.03104, found 258.03076. 
Methyl 3-((4-aminopyridin-2-yl)thio)propanoate (8): 
1H NMR (CDCl3), δ: 8.04 (1H, d, J = 5.7 Hz, H-6 Py), 6.42 (1H, d, J = 2.3 Hz, H-3 Py ), 6.27 (1H, 
dd, J = 5.7, 2.3 Hz, H-5 Py), 4.09 (2H, br s, NH2), 3.69 (3H, s, OCH3), 3.37 (2H, t, J = 7.2 Hz, H-3), 
2.76 (2H, t, J = 7.2 Hz, H-2); 13C NMR (CDCl3), δ: 172.63 (C-1), 158.30 (C-2 Py), 152.62 (C-4 Py), 
149.65 (C-6 Py), 107.15 (C-3 Py), 106.84 (C-5 Py), 51.72 (OCH3), 34.72 (C-2), 24.94 (C-3); IR 
(film): 3465, 3375, 3210, 3005, 2950, 1734, 1636, 1592, 1550, 1479, 1437, 1360, 1258, 1132, 981, 
823 cm−1; MS (EI) m/z: 212 (M+, 20), 181 (7), 179 (7), 155 (4), 154 (9), 153 (100), 152 (4), 139 
(12), 127 (20), 126 (26); HRMS: calcd for C9H12N2O2S 212.06195, found 212.06131. 
Methyl 3-(4-((3-phenylureido)pyridin-2-y)lthio)propanoate (10): 
1H NMR (CDCl3), δ: 8.10 (1H, d, J = 6.0 Hz, H-6 Py), 7.90 and 7.74 (1H each, each br s, two 
NH), 7.30–7.20 (4H, m, H-2/H-6 and H-3/H-5 Ph), 7.19 (1H, d, J = 1.9 Hz, H-3 Py), 7.05 (1H, m, 
H-4 Ph), 6.95 (1H, dd, J = 6.0, 1.9 Hz, H-5 Py), 3.67 (3H, s, OCH3), 3.35 (2H, t, J = 7.2 Hz, H-3), 
2.75 (2H, t, J = 7.2 Hz, H-2); 13C NMR (CDCl3), δ: 173.24 (C-1), 158.80 (C-2 Py), 152.83 (NCON), 
149.72 (C-6 Py), 146.24 (C-4 Py), 137.36 (C-1 Ph), 129.22 (C-3/C-5 Ph), 124.47 (C-4 Ph), 120.88 
(C-2/C-6 Ph), 110.57 (C-3 Py), 110.04 (C-5 Py), 52.01 (OCH3), 34.50 (C-2), 25.23 (C-3); IR (KBr): 
3392, 3354, 2950, 1722, 1698, 1579, 1540, 1439, 1275, 1200, 1083, 1002, 753 cm−1; MS (EI) m/z: 
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331 (M+, 5), 330 (1), 298 (1), 273 (2), 272 (13), 238 (14), 212 (8), 179 (82), 153 (36), 119 (45), 93 
(100); HRMS: calcd for C16H17N3O3S 331.09906, found 331.09777. 
3-((4-(3-Phenylureido)pyridin-2-yl)thio)propanoic acid (11, hapten s3): 
1H NMR (DMSO-d6), δ: 12.34 (1H, br s, OH), 9.52 and 9.27 (1H each, each br s, two NH), 8.21 
(1H, d, J = 5.7 Hz, H-6 Py), 7.50–7.45 (3H, m, H-2/H-6 Ph and H-3 Py), 7.28 (2H, t, J = 7.9 Hz, 
H-3/H-5 Ph), 7.11 (1H, dd, J = 5.7, 1.9 Hz, H-5 Py), 6.99 (1H, tt, J = 7.9, 1.2 Hz, H-4 Ph), 3.27 (2H, 
t, J = 7.0 Hz, H-5), 2.60 (1H, J = 7.0 Hz, H-2); 13C NMR (DMSO-d6), δ: 173.50 (C-1), 158.28 (C-2 
Py), 152.14 (NCON), 149.59 (C-6 Py), 146.93 (C-4 Py), 139.13 (C-1 Ph), 128.73 (C-3/C-5 Ph), 
122.26 (C-4 Ph), 118.49 (C-2/C-6 Ph), 109.25 (C-3 Py), 108.75 (C-5 Py), 34.62 (C-2), 24.83 (C-3); 
IR (KBr): 3550–2400, 3306, 2922, 1731, 1599, 1557, 1189, 1083, 751 cm−1; MS (EI) m/z: 317 (M+, 
0.5), 290 (0.6), 273 (0.8), 245 (1.5), 224 (1.2), 198 (5), 180 (10), 153 (17), 126 (67), 119 (71), 93 
(100); HRMS (FAB): calcd for C15H16N3O3S [M++1] 318.09124, found 318.09063; UV (PB), ε (280 
nm) = 11.31 mM−1cm−1, ε (260 nm) = 29.88 mM−1cm−1. 
3. Preparation of haptens 4Fs5 and 4Ms5 
N
S(CH2)4CO2CH3
H2N
12
H
N
H
N
NO
S(CH2)4CO2R
N C O
Benzene,
85%
LiOH
THF-H2O, rt
95%
F
F
(13)
14: R = CH3
15 (Hapten 4Fs5): R = H
N C O
Benzene,
67%
H3C
(16)
H
N
H
N
NO
S(CH2)4CO2R
LiOH
THF-H2O, rt
76%
H3C
17: R = CH3
18 (Hapten 4Ms5): R = H
 
Scheme S1. Preparation of haptens 4Fs5 and 4Ms5 
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5-(4-(3-((4-Fluorophenyl)ureido)pyridin-2-yl)thio)pentanoic acid (15, hapten 4Fs5)  
Methyl 5-((4-(3-(4-fluorophenyl)ureido)pyridin-2-yl)thio)pentanoate (14). Methyl 5-((4-
aminopyridin-2-yl)thio)pentanoate (12) was synthesized as described previously for the preparation 
of hapten s5.1 Then, 4-fluorophenyl isocyanate (13, 29 µL, 0.26 mmol) was added drop wise to a 
solution of the amino ester 12 (57 mg, 0.24 mmol) in benzene (1.0 mL). After 1 h 45 min at reflux 
under argon, the reaction mixture was diluted with hexane and the solid was filtrated affording the 
urea-methyl ester 14 (76 mg, 85%) as a white solid: mp 154–158 ºC (from acetone). 1H NMR 
(acetone-d6), δ: 8.43 and 8.31 (1H each, two s, two NH), 8.19 (1H, d, J = 5.7 Hz, H-6 Py), 7.56–7.52 
(3H, m, H-3 Py and H-2/H-6 Ph), 7.12 (1H, dd, J = 5.7, 1.8 Hz, H-5 Py), 7.10–7.04 (2H, m, H-3/H-5 
Ph), 3.61 (3H, s, CO2CH3), 3.17 (2H, t, J = 6.6 Hz, H-5), 2.37 (2H, t, J = 7.2 Hz, H-2), 1.73 (4H, m, 
H-3 and H-4); 13C NMR (acetone-d6), δ: 174.91(C-1), 161.42 (NCON), 160.40 (d, J = 239 Hz, C-4 
Ph), 153.89 (C-2 Py), 151.48 (C-6 Py), 148.76 (C-4 Py), 135.60 (d, J = 2.1 Hz, C-1 Ph), 122.69 (d, J 
= 7.5 Hz, C-2/C-6 Ph), 117.10 (d, J = 22 Hz, C-3/C-5 Ph), 111.25 and 111.11 (H-3 and H-5 Py), 
52.50 (CO2CH3), 34.85 (C-5), 30.91 (C-2), 30.74 (C-4), 25.83 (C-3); IR (KBr): 3360, 3131, 3071, 
3044, 2956, 2933, 2874, 1694, 1585, 1541, 1508, 1121, 837, 793 cm−1; MS (EI) m/z: 277 (2.5), 290 
(3), 277 (7.5), 267 (3), 266 (19), 263 (3), 240 (5), 236 (2.5), 235 (18), 233 (59), 219 (5), 209 (6), 179 
(82), 166 (86), 152 (64), 120 (20), 19 (22), 111 (100); HRMS (EI): calcd for C18H20FN3O3S [M+] 
377.12094, found 377.12086. 
5-(4-(3-((4-Fluorophenyl)ureido)pyridin-2-yl)thio)pentanoic acid (15, hapten 4Fs5). Hapten 4Fs5 
was obtained by hydrolysis of the methyl ester moiety of compound 14 (62 mg, 0.16 mmol) with 
LiOH·H2O (69 mg, 1.65 mmol) during 6 h, as described for hapten s3 (see Experimental section in 
the article). After ethyl ether extraction and acidification of the aqueous layer with KHSO4, followed 
by extraction with AcOEt and work up afforded nearly pure hapten 4Fs5 (15, 57 mg, 95%) as a 
white solid: mp 197–199 ºC (from DMSO/H2O). 1H NMR (DMSO-d6), δ: 12.03 (1H, broad s, OH), 
9.21 y 9.24 (1H each, two s, two NH), 8.20 (1H, d, J = 5.7 Hz, H-6 Py), 7.49–7.43 (3H, m, H-3 Py 
                                                 
 
1
 C. Suárez-Pantaleón, J.V. Mercader, C. Agulló, A. Abad-Somovilla and A. Abad-Fuentes, J. Agric. Food Chem. 2010, 
58, 8502–8511. 
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and H-2 and H-6 Ph), 7.07 (1H, dd, J = 5.7, 1.9 Hz, H-5 Py), 7.13 (2H, m, H-3 and H-5 Ph), 3.10 
(2H, t, J = 6.6 Hz, H-5), 2.24 (2H, t, J = 6.6 Hz, H-2), 1.63 (4H, m, H-3 and H-4); 13C NMR 
(DMSO-d6), δ: 174.4(C-1), 158.74 (NCON), 157.60 (d, J = 239 Hz, C-4 Ph), 152.13 (C-2 Py), 
149.57 (C-6 Py), 146.74 (C-4 Py), 135.34 (d, J = 2.3 Hz, C-1 Ph), 120.40 (d, J = 7.7 Hz, C-2/C-6 
Ph), 115.28 (d, J = 22 Hz, C-3 and C-5 Ph), 109.16 and 108.75 (H-3 and H-5 Py), 33.24 (C-5), 28.76 
and 28.54 (C-2 and C-4), 23.73 (C-3); IR (KBr): 3340–3276, 3153, 3073, 2956, 2934, 2918, 2718, 
1565, 1509, 1192, 830, 740 cm−1; MS (EI) m/z: 207 (1), 138 (5), 137 (70), 112 (4), 111 (53), 110 (6), 
108 (4), 73 (100); HRMS (FAB): calcd for C17H19FN3O3S [M+ + 1] 364.11312, found 364.11276; 
UV (PB), ε (280 nm) = 8.00 mM−1cm−1, ε (260 nm) = 25.44 mM−1cm−1. 
5-(4-((3-p-Tolylureido)pyridin-2-yl)thio)pentanoic acid (18, hapten 4Ms5) 
Methyl 5-((4-(3-p-tolylureido)pyridin-2-yl)thio)pentanoate (17). p-Tolyl isocyanate (16, 32 µL, 
0.25 mmol) was added drop wise to a solution of methyl 5-((4-aminopyridin-2-yl)thio)pentanoate 
(12, 55 mg, 0.23 mmol) in dry benzene (1.1 mL) under inert atmosphere. The reaction was stirred for 
1 h 45 min at reflux and then it was diluted with hexane and filtrated to afford the corresponding 
urea-methyl ester 17 (57 mg, 67%) as a yellowish solid: mp 136–140 ºC (from acetone). 1H NMR 
(acetone-d6), δ: 8.37 and 8.17 (1H each, two s, two NH), 8.19 (1H, d, J = 5.8 Hz, H-6 Py), 7.54 (1H, 
d, J = 1.6 Hz, H-3 Py), 7.40 (2H, m, H-2 and H-6 Ph), 7.13–7.06 (3H, m, H-5 Py and H-3 and H-5 
Ph), 3.61 (3H, s, CO2CH3), 3.17 (2H, t, J = 7.0 Hz, H-5), 2.35 (2H, t, J = 7.0 Hz, H-2), 2.27 (3H, s, 
CH3-Ph), 1.73 (4H, m, H-3 and H-4); 13C NMR (acetone-d6), δ 174.91(C-1), 161.36 (NCON), 
153.81 (C-2 Ph), 151.44 (C-6 Py), 148.88 (C-4 Py), 138.53 (C-4 Ph), 133.91 (C-1 Ph), 131.07 (C-3 
and C-5 Ph), 120.94 (C-2 and C-6 Ph), 111.17 and 111.06 (H-3 and H-5 Py), 52.50 (CO2CH3), 34.85 
(C-5), 30.92 (C-2), 30.74 (C-4), 25.83 (C-3), 21.72 (CH3-Ph); IR (KBr): 3364, 1698, 1595, 1535, 
1480, 1362, 1168, 821, 630 cm−1; MS (EI) m/z: 373 (3), 286 (3), 273 (10), 266 (18), 259 (4), 240 (7), 
235 (18), 233 (4), 219 (5), 179 (75), 166 (77), 165 (19), 153 (28), 106 (100); HRMS (EI): calcd for 
C19H23N3O3S [M+] 373.14601, found 373.14703. 
5-((4-(3-p-Tolylureido)pyridin-2-yl)thio)pentanoic acid (18, hapten 4Ms5). The hydrolysis of the 
ester moiety of 17 (57 mg, 0.15 mmol) was carried out essentially as described for haptens s3 and 
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4Fs5, using LiOH·H2O (65 mg, 1.54 mmol). After ethyl ether extraction and acidification of the 
aqueous layer, the precipitated solid was filtered and dried under vacuum to give pure hapten 4Ms5 
(18, 42 mg, 76%) as a white solid: mp 198–201 ºC (from MeOH). 1H NMR (DMSO-d6), δ: 12.02 
(1H, broad s, OH), 9.06 and 8.79 (1H each, two s, two NH), 8.19 (1H, d, J = 5.6 Hz, H-6 Py), 7.43 
(1H, d, J = 1.7 Hz, H-3 Py), 7.33 (2H, m, H-2 and H-6 Ph), 7.10 (2H, m, H-3 and H-5 Ph), 7.06 (1H, 
dd, J = 5.7, 1.7 Hz, H-5 Py), 3.10 (2H, t, J = 7.0 Hz, H-5), 2.24 (2H, t, J = 7.3 Hz, H-2), 1.63 (4H, m, 
H-3 and H-4); 13C NMR (DMSO-d6), δ: 174.26(C-1), 158.71 (NCON), 151.98 (C-2 Ph), 149.55 (C-
6 Py), 146.75 (C-4 Py), 136.35 (C-4 Ph), 131.28 (C-1 Ph), 129.15 (C-3 and C-5 Ph), 118.60 (C-2 
and C-6 Ph), 109.10 and 108.66 (H-3 and H-5 Py), 33.13 (C-5), 28.74 and 28.53 (C-2 and C-4), 
23.67 (C-3), 20.29 (CH3-Ph); IR (KBr): 3115, 3049, 3022, 2945, 1720, 1606, 1560, 1508, 1406, 
1315, 1204, 841, 818 cm−1; MS (EI) m/z: 133 (10), 132 (5), 108 (1), 107 (14), 106 (18), 105 (1.5), 91 
(2), 73 (100); HRMS (FAB): calcd for C18H22N3O3S [M+ + 1] 360.13819, found 360.13877; UV 
(PB), ε (280 nm) = 14.51 mM−1cm−1, ε (260 nm) = 30.75 mM−1cm−1. 
4. Preparation of CPPU analogues thio-CPPU and BzClPyA 
 
 
Scheme S2. Preparation of CPPU analogues thio-CPPU and BzClPyA 
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1-(2-Chloro-4-pyridyl)-3-phenylthiourea (21, thio-CPPU) 
Phenyl isothiocyanate (20, 354 µL, 1.86 mmol) was added drop wise via syringe to a solution of 
4-amino-2-chloropyridine (19, 217 mg, 1.69 mmol)2 in dry CH2Cl2 (2.0 mL) and then stirred at rt for 
120 h. The reaction mixture was then extracted with CH2Cl2, washed with water and brine, and dried 
over Mg2SO4 to give the crude product that was purified by column chromatography, using 
CH3Cl/MeOH 9:1 as eluent. The eluted fraction containing the product was extracted again with 
AcOEt and washed with 1M HCl. The organic layer was then concentrated and dried affording thio-
CPPU (21, 154 mg, 35%) as a yellow solid; mp 135–138 ºC (from MeOH). 1H NMR (DMSO-d6), δ: 
10.40 (1H, s, NH), 10.37 (1H, s, NH), 8.24 (1H, d, J = 5.6 Hz, H-6 Py), 7.87 (1H, d, J = 1.8 Hz, H-3 
Py), 7.54 (1H, dd, J = 5.6, 1.8 Hz, H-5 Py), 7.49 (2H, dt, J = 7.5, 1.2 Hz, H-2/H-6 Ph), 7.39 (2H, t, J 
= 7.5, Hz, H-3/H-5 Ph), 7.19 (1H, tt, J = 7,5, 1,2Hz, H-4 Ph); 13C NMR (DMSO-d6), δ: 179.08 
(NCON), 150.25 (C-4 Py), 149.72 (C-6 Py), 149.41 (C-2 Py), 138.62 (C-1 Ph), 128.61 (C-2/C-6 Ph), 
125.19 (C-4 Ph), 123.79 (C-3/C-5 Ph), 114.62 and 114.15 (C-3 and C-5 Py); IR (KBr):  3152, 3115, 
2968, 1589, 1569, 1528, 1488, 1190, 749 cm−1; MS (EI) m/z: 263 (8), 262 (2), 230 (15), 229 (100), 
195 829, 194 (16), 178 (2), 173 (20), 170 (50); HRMS (EI): calcd for C12H10ClN3S 263.02839, 
found 263.02904. 
N-(2-Chloro-4-pyridyl)-2-phenylacetamide (23, BzClPyA)  
2-phenylacetyl chloride (22, 202 µL, 1.52 mmol) was added to a solution containing 4-amino-2-
chloropyridine (19, 98 mg, 0.76 mmol) and N,N’-diisopropil ethylamine (i(Pr)2NEt, 290  µL, 1.68 
mmol) in anhydrous 1,2-dichloroethane (2.0 mL). The mixture was stirred at rt for 1.5 h under inert 
atmosphere, then the solvent was eliminated and the crude product was diluted with water and 
extracted three times with EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4, and concentrated under vacuum to obtained an oil that was purified by column 
chromatography, using CH3Cl as eluent, to afford pure BzClPyA (23, 155 mg, 82%) as a slightly 
colored oil. 1H NMR (CDCl3), δ: 8.70 (1H, s, NH), 8.12 (1H, d, J = 5.6 Hz, H-6 Py), 7.59 (1H, d J = 
                                                 
2
 S. Kasmi-Mir, A. Djafri, L. Paquin, J. Hamelin and M. Rahmouni, Molecules, 2006, 11, 597–602. 
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1.6 Hz, H-3 Py), 7.34–7.21 (6H, m, H-5 Py and H-2/H-3/H-4/H-5/H-6 Ph), 3.67 (CH2O); 13C NMR 
(CDCl3), δ: 170.46 (CON), 152.12 (C-2-Py), 149.79 (C-6 Py), 147.34 (C-4 Py), 133.41 (C-1 Ph), 
129.17 (C-2/C-6 Ph), 129.04 (C-3/C-5 Ph), 127.69 (C-4 Ph), 113.56 and 112.58 (C-3 and C-5 Py), 
44.38 (CH2O); IR (KBr): 3263, 3161, 3062, 3029, 1685, 1581, 1509, 1371, 1266, 1159, 1126,1079, 
837, 731, 718, 694 cm−1; MS (EI) m/z: 246 (31), 131 (2), 129 (8), 119 (3), 118 (24), 92 (29), 91 
(100); HRMS (EI): calcd for C13H11ClN2O 246.05599, found 246.05649.
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5. Preparation of protein conjugates 
Immunizing conjugate. The active ester method was used to couple haptens m2 and s3 to bovine 
serum albumin (BSA). Typically, a 100 mM hapten solution was prepared in N,N-
dimethylformamide (DMF) and mixed with 1 molar equivalent of N-hydroxysuccinimide and 1 
molar equivalent of N,N’-dicyclohexylcarbodiimide also in DMF. Additional DMF was added to 
bring the final concentration of all reagents to 50 mM. The hapten was activated overnight at rt in 
amber vials. The day after, the reaction was centrifuged and the supernatant was collected. Next, 
400 µL of activated m2 or s3 hapten solution was added drop wise to 2.0 mL of a 15 mg/mL BSA 
solution in 50 mM sodium carbonate–bicarbonate buffer, pH 9.6 (CB). The coupling reaction was 
incubated during 4 h at rt with moderate stirring. The initial hapten-to-protein molar ratio (MR) in 
the mixture was approximately 44:1. Finally, the conjugate was separated from uncoupled hapten by 
gel filtration on Sephadex G-25, using 100 mM sodium phosphate buffer, pH 4.4 (PB) as eluent. The 
degree of hapten-to-protein conjugation was measured spectrophotometrically. If conjugation 
occurred, the UV–vis spectrum of the conjugate was slightly different from that of the free protein. 
Therefore, the final average hapten-to-protein MR was calculated from the absorbance value at 280 
nm by assuming that the molar absorption of the hapten and the protein were the same for the free 
and the conjugated forms. The purified conjugate was diluted to 1.0 mg/mL with PB and stored at 
−20 ºC. The calculated final hapten-to-protein MR are listed in Table S1. 
Coating conjugates. Haptens m2, s3, 4Fs5, and 4Ms5 were linked to ovalbumin (OVA) by the 
mixed anhydride method. Typically, 200 µL of a solution with the hapten, tributylamine, and 
isobutyl chloroformate in DMF were prepared. The concentration of the reagents in the solution was 
90 mM. After 1 h at rt with gentle stirring, 100 µL of the solution containing the activated hapten 
was added drop wise to 2.0 mL of a 15 mg/mL solution of OVA in CB. In this case, the initial 
hapten-to-protein MR was approximately 13:1. The coupling reaction was incubated during 2.5 h in 
the same conditions as described before and then the conjugates were purified following the same 
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procedure. MRs were determined by UV spectrophotometry. A solution of each conjugate was 
prepared at a concentration of 1.0 mg/mL in PB containing 0.01% (w/v) thimerosal, and it was 
stored at −20 ºC for daily usage. The final MRs can be found in Table S1. Hapten s3 was also 
coupled to OVA by the active ester method using an initial hapten-to-protein MR of 15:1. 
Enzyme tracers. A 1/10 dilution of the activation mixture in DMF, prepared for the previous 
conjugates, was employed containing 0.5 µmol of the activated hapten. This dilution was added to 
1.0 mL of a solution of horseradish peroxidase (HRP) in CB at a concentration of 2.2 mg/mL. The 
initial hapten-to-protein MR in the mixture was 10:1. The conjugation was incubated during 4 h and 
then the enzyme tracer was separated from the uncoupled hapten as described before. The final MR 
was calculated using, in this case, the absorbance values obtained at 400 nm and 280 nm. A working 
solution of the enzyme tracer was prepared in PBS containing 1% (w/v) BSA and 0.01% (w/v) 
thimerosal at a concentration of 0.5 mg/mL and was stored for its daily usage at 4 ºC. The remaining 
fraction was stored in elution buffer at −20 ºC. For the final MRs see Table S1. Hapten s3 was also 
coupled to HRP by the active ester method using an initial hapten-to-protein MR of 10:1. 
 
Table S1. Hapten-to-protein MRs of conjugates 
 Carrier protein 
Hapten BSA OVA HRP 
p2 24 2.8 2.1 
p6 30 2.4 3.4 
CldPhUp6 -a 4.5 7.5 
PhPyUp6 - 2.5 1.5 
m2 34 1.6 1.3 
m6 34 3.0 3.2 
s3 26 4.0b 1.3b 
s5 18 6.4 3.3 
4Fs5 - 5.5 3.5 
4Ms5 - 5.9 3.8 
a Not prepared. b These assay conjugates were prepared by the active ester 
method. 
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6. Monoclonal antibody production 
Immunization and cell fusion. Female BALB/c mice (8–10 weeks old) were immunized by 
intraperitoneal injections with BSA–m2, BSA–m6, BSA–s3, and BSA–s5 conjugates (typically 4 
animals per immunogen). Initially, animals received a first dose of immunogen consisting of 100 µg 
of conjugate in PB as a 1:1 emulsion with complete Freund’s adjuvant (200 µL per mouse). Mice 
received two additional boosts at intervals of three weeks with the same amount of immunogen 
emulsified, in this case, with incomplete Freund’s adjuvant. Finally, four days before cell fusions, 
every mouse received a last immunization containing 100 µg of conjugate diluted in sterile PBS. 
Cell fusions were carried out following standard chemical fusion procedures3 using polyethylene 
glycol as fusing agent at a cellular ratio lymphocyte:myeloma of 4:1. The fused cells were cultured 
in 96-well culture plates at a density between 1.5 × 105 and 2.5 × 105 cells per well in DMEM 
supplemented with 15% (v/v) fetal bovine serum. 
Hybridoma selection. Approximately 10 to 12 days after the fusions, the supernatants of the 
cultured plates were evaluated in order to identify antibody-secreting hybridomas with the ability to 
recognize both the coating conjugate and the free analyte. Typically, ELISA plates were coated with 
the homologous conjugate at a concentration of 1 µg/mL. The supernatants were evaluated 
simultaneously in adjacent ELISA wells: one as blank and the other with 1 µM forchlorfenuron 
(CPPU). Those clone-containing wells affording signal intensities in the absence of analyte close to 
saturation and more than 50% inhibition under competitive conditions were selected and further 
cloned by limiting dilution. This process was repeated as many times as necessary in order to 
guarantee the stability and the monoclonal character of the cell lines. Few positive signals were 
observed in the screening assays of cell fusions from s3 immunized mice. Therefore, two additional 
mice (s3#5 and s3#6) were immunized with the same conjugate but the cell-fusion screening assays 
were performed with the OVA–s5 conjugate. Using this strategy it was possible to stabilize 5 
additional hybridomas (Table S2). 
                                                 
3
 J.V. Mercader and A. Montoya, J. Agric. Food Chem., 1999, 47, 1276–1284. 
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Monoclonal antibody purification. Immunoglobulins were purified from late stationary phase 
culture supernatants by ammonium sulfate precipitation followed by affinity chromatography 
following the manufacturer’s instructions. Stock solutions of every antibody were prepared in PBS 
containing 1% (w/v) BSA and 0.01% (w/v) thimerosal and they were stored at 4 ºC for daily usage. 
The remaining volume was 2-fold precipitated with a saturated ammonium sulfate solution for its 
long-term conservation and it was stored at 4 ºC. 
 
Table S2. Summary of cell fusions performed with mice 
immunized with conjugates BSA–m2, BSA–m6, BSA–s3, and 
BSA–s5 
  Wells  
Immunized 
mouse 
Growth 
yielda Cultured Positiveb Competitivec 
Stabilized 
hybridoma 
m2#1 74 384 11 5 4 
m2#2 74 480 345 304 0 
m2#3 ---d     
m2#4 ---     
m6#1 42 384 13 10 1 
m6#2 ---     
m6#3 67 384 9 1 1 
m6#4 73 288 210 195 2 
s3#1e 79 288 0 0 0 
s3#2e 49 288 225 171 1 
s3#3e 54 240 0 0 0 
s3#4e 21 288 3 2 0 
s3#5f 76 576 20 9 4 
s3#6f 62 672 10 2 1 
s5#1 77 384 89 77 2 
s5#2 85 384 56 43 1 
s5#3 77 672 491 472 4 
s5#4 17 192 0 0 0 
a Percentage of cultured wells with cellular growth by visual inspection at day 11 
after fusion. b Wells with cellular growth affording A492 ≥ 1 in the absence of 
analyte. c Wells with an inhibition of the signal intensity ≥ 50% in the presence of 
1 µ M CPPU. d These mice died during the immunization process. e The 
screening assay was performed with the conjugate OVA–s3 prepared by the 
mixed anhydride method. f The screening was performed with the heterologous 
conjugate OVA–s5. 
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7. Standard curve parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Antibody-distance data 
 
 
 
 
 
 
 
 
 
Table S3. Curve parameters of the selected cELISAs 
i-cELISA 
mAb 
OVA 
conjugate 
[OVA conj.] 
(µ g/mL) 
[mAb] 
(ng/mL) Amax slope IC50 (nM) 
p6#24 4Ms5 1.0 30 1.25 ± 0.02 −1.24 ± 0.13 0.16 ± 0.01 
m2#15 m2 0.1 30 1.06 ± 0.09 −1.31 ± 0.13 0.22 ± 0.04 
s3#51 p2 1.0 30 1.26 ± 0.07 −1.23 ± 0.07 0.08 ± 0.01 
  
d-cELISA 
mAb 
Enzyme 
tracer 
[Tracer] 
(ng/mL) 
[mAb] 
(µ g/mL) Amax slope IC50 (nM) 
p2#61 m6 10 1.0 1.23 ± 0.03 −1.13 ± 0.09 0.23 ± 0.01 
m2#15 m6 3 1.0 0.94 ± 0.07 −1.08 ± 0.10 0.32 ± 0.04 
s5#34 p6 10 1.0 0.76 ± 0.07 −1.36 ± 0.06 0.21 ± 0.04 
Table S4. Minimum and maximum Kendall’s tau correlation coefficient (τ) between antibodies by 
comparison of pairs of clustersa 
 Lowest similarity  Highest similarity Confronted 
clusters  τ b Representative pairs  τ Representative pairs 
A1 vs A1  0.41 m6#43 vs m2#13  0.96 p2#63 vs p2#62 
A1 vs A2  0.16 m6#43 vs p6#33  0.82 m2#12 vs p2#65/m2#14 
A1 vs B1  −0.21 m6#43 vs s5#11  0.38 Rm6#2 vs Rs5#1 
A1 vs B2  −0.25 m6#43 vs m6#13  0.51 Rm6#1 vs s5#21 
A2 vs A2  0.60 p6#42 vs p6#33  0.98 m2#15 vs p2#65; m6#31 vs p2#65/m2#14 
A2 vs B1  −0.18 p2#66 vs s5#32  0.49 p6#21 vs Rs5#1/s5#35; p6#33 vs Rs5#1 
A2 vs B2  −0.08 p6#42 vs s3#22  0.60 p6#33 vs s5#21 
B1 vs B1  0.01 p6#41 vs s5#32  0.80 Rs5#1 vs Rs5#2 
B1 vs B2  −0.05 s5#35 vs s3#22  0.76 Rs5#2 vs s3#52 
B2 vs B2  0.21 s3#22 vs s3#52/s5#34/s3#53  0.91 s3#52 vs s5#34 
a The combinations for antibodies inside the same cluster are indicated in bold-type letter. b τ ranges from −1 to 1, indicating 
the lowest and highest similarity, respectively. 
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9. Copies of 1H NMR, 13C NMR, and mass spectra of haptens m2, s2, 4Fs5, and 4Ms5 
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1H NMR spectrum of 2-(3-(3-(2-chloropyridin-4-yl)ureido)acetic acid (4, hapten m2) in DMSO-d6 
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13C NMR spectrum of 2-(3-(3-(2-chloropyridin-4-yl)ureido)phenyl)acetic acid (4, hapten m2) in CDCl3/DMSO-d6 
40.80 
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Mass spectrum of 2-(3-(3-(2-chloropyridin-4-yl)ureido)phenyl)acetic acid (4, hapten m2) 
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1H NMR spectrum of 3-((4-(3-phenylureido)pyridin-2-yl)thio)propanoic acid  (11, hapten s3) in DMSO-d6 
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13C NMR spectrum of 3-((4-(3-phenylureido)pyridin-2-yl)thio)propanoic acid (11, hapten s3) in DMSO-d6 
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Mass spectrum of 3-((4-(3-phenylureido)pyridin-2-yl)thio)propanoic acid (11, hapten s3) 
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1H NMR spectrum of 5-(4-(3-((4-fluorophenyl)ureido)pyridin-2-yl)thio)pentanoic acid (15, hapten 4Fs5) in DMSO-d6 
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13C NMR spectrum of 5-(4-(3-((4-fluorophenyl)ureido)pyridin-2-yl)thio)pentanoic acid (15, hapten 4Fs5) in DMSO-d6 
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Mass spectrum of 5-(4-(3-((4-fluorophenyl)ureido)pyridin-2-yl)thio)pentanoic acid (15, hapten 4Fs5) 
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1H NMR spectrum of 5-((4-(3-p-tolylureido)pyridin-2-yl)thio)pentanoic acid (18, hapten 4Ms5) in DMSO-d6 
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13C NMR spectrum of 5-((4-(3-p-tolylureido)pyridin-2-yl)thio)pentanoic acid (18, hapten 4Ms5) in DMSO-d6 
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Mass spectrum 5-((4-(3-p-tolylureido)pyridin-2-yl)thio)pentanoic acid (18, hapten 4Ms5). 
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